SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer☆

Annals of Oncology · Elsevier

Аннотация

Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): A.C. Garrido-Castro, S.E. Kim, T. Li, J. Desrosiers, R. Nanda, Y. Abdou, A.S. Clark, R.L. Sacks, T. O’Connor, N. Sinclair, S. Lo, G. Augdahl, E. Wrabel, M. DiLullo, T. Rahman, A. Patel, M.E. Hughes, J. Baginska, P.B. Lange, T. O’Meara

Читать у издателя →

Похожие статьи